Skip to main content

Variants in eukaryotic translation initiation factor 4G1 in sporadic Parkinson’s disease

neurogenetics volume 13, pages 281–285 (2012)Cite this article

Abstract

Recently, mutations in eukaryotic translation initiation factor 4G1 (EIF4G1) were reported as a rare cause of familial Parkinson’s disease (PD). We screened the 33 exons of EIF4G1 by high-resolution melting curve analysis for variants in our Central European cohort of 376 PD cases. Variant frequency was assessed in a total of 975 PD cases and 1,014 general population controls. Eight novel nonsynonymous and four synonymous variants were identified. In our cohort, novel and previously identified nonsynonymous variants were very rare. Although it is possible that our general population controls also comprise individuals who have or could develop PD in the future, the presence of the original mutation (EIF4G1 p.Arg1205 His) in three controls only, raises questions about the causality of this variant with regard to PD.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Chartier-Harlin MC, Dachsel JC, Vilariño-Güell C et al (2011) Translation initiator EIF4G1 in familial Parkinson disease. Am J Hum Genet 89:398–406

    PubMed  CAS  Article  Google Scholar 

  2. Wichmann HE, Gieger C, Illig T (2005) KORA-gen—resource for population genetics, controls and a broad spectrum of disease phenotypes. Gesundheitswesen 67(Suppl 1):26–30

    Article  Google Scholar 

  3. Tucci A, Charlesworth G, Sheerin UM et al (2012) Study of the genetic variability in a Parkinson’s disease gene: EIF4G1. Neurosci Lett (in press)

  4. Exome Variant Server, NHLBI Exome Sequencing Project (ESP), Seattle, WA. http://evs.gs.washington.edu/EVS/. Accessed 14 May 2012.

  5. Schwarz JM, Rödelsperger C, Schuelke M et al (2010) MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 8:575–576

    Article  Google Scholar 

  6. Adzhubei IA, Schmidt S, Peshkin L et al (2010) A method and server for predicting damaging missense mutations. Nat Methods 7:248–249

    PubMed  CAS  Article  Google Scholar 

  7. Satake W, Nakabayashi Y, Mizuta I et al (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson`s disease. Nat Genet 41:1303–1307

    PubMed  CAS  Article  Google Scholar 

  8. Zimprich A, Biskup S, Leitner P et al (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601–607

    PubMed  CAS  Article  Google Scholar 

  9. Gehrke S, Imai Y, Sokol N, Lu B (2010) Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466:637–641

    PubMed  CAS  Article  Google Scholar 

Download references

Acknowledgments

We are very grateful to Jelena Golic, Susanne Lindhof, Katja Junghans, Regina Feldmann, and Sybille Frischholz for expert technical assistance.

Competing interests

The authors declare that they have no conflict of interest with regard to the above study. Full financial disclosures are listed below.

Dr. Schulte received a postdoctoral fellowship from Technische Universität München, Munich, Germany. Dr. Mollenhauer has received speaker honoraria from Orion Corporation and GlaxoSmithKline; serves as an Associate Editor for the Journal of Alzheimer Disease; holds or has pending patents re: Method of differentially diagnosing dementias; Novel ELISA-based quantification of alpha-synuclein proteins in cerebrospinal fluid and peripheral blood products using 384-well plates; and MicroRNA expression profiling of cerebrospinal fluid; serves as a consultant for Bayer Schering Pharma AG; and receives research support from Teva Pharmaceutical Industries Ltd., Desitin Pharmaceuticals, GmbH, Boehringer Ingelheim, GE Healthcare, the Michael J. Fox Foundation for Parkinson’s Research, the American Parkinson’s Disease Association, and the Stifterverband für die Deutsche Wissenschaft (Dr. Werner Jackstädt-Stipend). Dr. Zimprich reports no disclosures. Dr. Bereznai receives research support from the Hungarian National Innovation Office (TÁMOP-4-2-1/B-03/1/KMR-2010-001). Dr. Lichtner reports no disclosures. Dr. Haubenberger received an NINDS Intramural Competitive Fellowship and research report from the Austrian Science Fund (Erwin Schroedinger Fellowship, project# J2783-B09) and the NINDS Intramural Research Program. Dr. Pirker has received speaker honoraria and travel compensation from Boehringer Ingelheim, Novartis, Abbott Pharmaceuticals, Medtronic, and UCB. Dr. Brücke has received honoraria for lecturing and travel compensation from CSC, USB, Boehringer Ingelheim, Novartis, Aventis, GE Healthcare, Lundbeck, Merz, GlaxoSmithKline, and Pfizer. Dr. Molnar serves/has served on scientific advisory boards for Genzyme Europe B.V., received speaker honoria from Roche, serves as the Editor-in-Chief of the Hungarian edition of Neurology, and receives research support from the Hungarian National Innovation Office (TÁMOP-4-2-1/B-03/1/KMR-2010-001). Dr. Peters and Dr. Gieger report no disclosures. Dr. Trenkwalder serves on scientific advisory boards for Boehringer Ingelheim, Cephalon, Inc., UCB, Novartis, Mundipharma International Limited, and Solvay Pharmaceuticals, Inc.; has received speaker honoraria from Boehringer Ingelheim, Cephalon, Inc., UCB, Novartis, Pfizer Inc, and GlaxoSmithKline; serves on the editorial boards of Sleep Medicine and Movement Disorders and as an Associate Editor for Focus on Parkinson Disease. Dr. Winkelmann serves on a scientific advisory board for UCB; has received speaker honoraria from UCB and Boehringer Ingelheim; has filed a patent re: Winkelmann et al. Nat Genet 2007; and receives research support from the German RLS foundation, the Deutsche Forschungsgemeinschaft (DFG) and the Fritz Thyssen Foundation.

Funding

The study depicted herein was funded by institutional funding from Helmholtz Zentrum München, Munich, Germany. Recruitment of case and control cohorts was supported by institutional (Helmholtz Zentrum München, Munich, Germany) and government funding from the German Bundesministerium für Bildung und Forschung (03.2007-02.2011 FKZ 01ET0713), and the Hungarian National Innovation Office (TAMOP-4-2-1/B-03/1/KMR-2010-001).

Author information

Affiliations

  1. Neurologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Ismaningerstr. 22, 81675, Munich, Germany

    Eva C. Schulte & Juliane Winkelmann

  2. Institut für Humangenetik, Helmholtz Zentrum München, Munich, Germany

    Eva C. Schulte, Peter Lichtner & Juliane Winkelmann

  3. Paracelsus Elena Klinik, Kassel, Germany

    Brit Mollenhauer & Claudia Trenkwalder

  4. Neurologische Klinik, Georg August Universität, Göttingen, Germany

    Brit Mollenhauer & Claudia Trenkwalder

  5. Department of Neurology, Medical University of Vienna, Vienna, Austria

    Alexander Zimprich, Dietrich Haubenberger & Walter Pirker

  6. Center for Molecular Neurology, Department of Neurology, Semmelweis University, Budapest, Hungary

    Benjamin Bereznai & Maria J. Molnar

  7. Institut für Humangenetik, Technische Universität München, Munich, Germany

    Peter Lichtner & Juliane Winkelmann

  8. Department of Neurology, Wilhelminenspital, Vienna, Austria

    Thomas Brücke

  9. Institute of Epidemiology II, Helmholtz Zentrum München, Munich, Germany

    Annette Peters

  10. Institute of Genetic Epidemiology, Helmholtz Zentrum München, Munich, Germany

    Christian Gieger

Authors
  1. Eva C. Schulte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brit Mollenhauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexander Zimprich
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Benjamin Bereznai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter Lichtner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dietrich Haubenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Walter Pirker
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Thomas Brücke
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Maria J. Molnar
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Annette Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Christian Gieger
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Claudia Trenkwalder
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Juliane Winkelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juliane Winkelmann.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Schulte, E.C., Mollenhauer, B., Zimprich, A. et al. Variants in eukaryotic translation initiation factor 4G1 in sporadic Parkinson’s disease. Neurogenetics 13, 281–285 (2012). https://doi.org/10.1007/s10048-012-0334-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10048-012-0334-9

Keywords

  • Genetics
  • Rare variants
  • Parkinson’s disease
  • EIF4G1